Keros Therapeutics (KROS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

KROS Stock Forecast

Keros Therapeutics stock forecast is as follows: an average price target of $102.60 (represents a 89.51% upside from KROS’s last price of $54.14) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

KROS Price Target

The average price target for Keros Therapeutics (KROS) is $102.60 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $107.00 to $96.00. This represents a potential 89.51% upside from KROS's last price of $54.14.

KROS Analyst Ratings

Buy

According to 6 Wall Street analysts, Keros Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KROS stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Keros Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Kelly Shi	Jefferies	$107.00	$62.02	72.52%	97.64%
Nov 05, 2024	Srikripa Devarakonda	Truist Financial	$100.00	$62.02	61.24%	84.71%
Sep 23, 2024	Vamil Divan	Guggenheim	$96.00	$55.80	72.04%	77.32%
Jun 18, 2024	Joseph Catanzaro	Piper Sandler	$105.00	$44.65	135.16%	93.94%
Dec 13, 2022	-	BTIG	$105.00	$49.98	110.08%	93.94%
Jul 27, 2022	Julian Harrison	BTIG	$80.00	$31.79	151.65%	47.77%
May 18, 2022	Joseph Catanzaro	Piper Sandler	$120.00	$39.92	200.60%	121.65%

Row per page

Go to

The latest Keros Therapeutics stock forecast, released on Nov 05, 2024 by Kelly Shi from Jefferies, set a price target of $107.00, which represents a 72.52% increase from the stock price at the time of the forecast ($62.02), and a 97.64% increase from KROS last price ($54.14).

Keros Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	2	3	4
Avg Price Target	$103.50	$101.00	$102.00
Last Closing Price	$54.14	$54.14	$54.14
Upside/Downside	91.17%	86.55%	88.40%

In the current month, the average price target of Keros Therapeutics stock is $103.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 91.17% increase as opposed to Keros Therapeutics's last price of $54.14. This month's average price target is up 2.48% compared to last quarter, and up 1.47% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 05, 2024	Jefferies	-	Buy	Initialise
Oct 24, 2024	Cantor Fitzgerald	-	Overweight	Initialise
Sep 23, 2024	Guggenheim	-	Buy	Initialise
Jun 24, 2024	Oppenheimer	-	Outperform	Initialise
Jun 18, 2024	Piper Sandler	Overweight	Overweight	Hold
Dec 13, 2022	BTIG	Buy	Buy	Hold
Oct 10, 2022	Piper Sandler	Overweight	Overweight	Hold
Jul 27, 2022	BTIG	-	Buy	Initialise

Row per page

Go to

Keros Therapeutics's last stock rating was published by Jefferies on Nov 05, 2024. The company Initialise its KROS rating from "null" to "Buy".

Keros Therapeutics Financial Forecast

Keros Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Dec 22	Mar 22	Sep 20	Mar 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$81.57K	$97.00K	$115.35K	$137.18K	$16.67K	$14.29K	$14.29K	$14.29K	$46.15K	$388.00K	$37.00K	$216.67K	$325.00K	$1.20M	$6.00M	$62.50K	$83.33K
High Forecast	$122.35K	$145.50K	$173.03K	$205.77K	$25.00K	$21.43K	$21.43K	$21.43K	$76.92K	$582.00K	$37.00K	$325.00K	$487.50K	$1.80M	$6.00M	$62.50K	$83.33K
Low Forecast	$40.78K	$48.50K	$57.68K	$68.59K	$8.33K	$7.14K	$7.14K	$7.14K	$15.38K	$194.00K	$37.00K	$108.33K	$162.50K	$600.00K	$6.00M	$62.50K	$83.33K
# Analysts	4	4	4	4	3	3	3	5	7	3	3	6	3	2	4	3	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Keros Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KROS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Keros Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Dec 22	Mar 22	Sep 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	7	3	3	6	3	2	4	3	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-37.31M	$-35.64M	$-29.72M	$-24.07M	$-11.96M	$-12.00M
Avg Forecast	$-16.31K	$-19.40K	$-23.07K	$-27.43K	$-3.33K	$-2.86K	$-2.86K	$-2.86K	$-9.23K	$-77.60K	$-7.25K	$-43.33K	$-65.00K	$-240.00K	$-19.87M	$-12.25K	$-110.99M
High Forecast	$-8.16K	$-9.70K	$-11.54K	$-13.72K	$-1.67K	$-1.43K	$-1.43K	$-1.43K	$-3.08K	$-38.80K	$-7.25K	$-21.67K	$-32.50K	$-120.00K	$-15.90M	$-12.25K	$-88.79M
Low Forecast	$-24.47K	$-29.10K	$-34.60K	$-41.15K	$-5.00K	$-4.29K	$-4.29K	$-4.29K	$-15.38K	$-116.40K	$-7.25K	$-65.00K	$-97.50K	$-360.00K	$-23.85M	$-12.25K	$-133.18M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	861.10%	548.27%	123.83%	1.21%	976.81%	0.11%

undefined analysts predict KROS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Keros Therapeutics's previous annual EBITDA (undefined) of $NaN.

Keros Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Dec 22	Mar 22	Sep 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	7	3	3	6	3	2	4	3	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-37.51M	$-32.74M	$-29.72M	$-24.19M	$-12.04M	$-11.89M
Avg Forecast	$-36.92M	$-36.97M	$-37.02M	$-36.94M	$-51.01M	$-51.49M	$-52.21M	$-51.76M	$-50.95M	$-46.16M	$-45.43M	$-48.34M	$-40.54M	$-39.61M	$-19.97M	$-21.48M	$-126.41M
High Forecast	$-12.92M	$-12.94M	$-12.96M	$-12.93M	$-17.85M	$-18.02M	$-18.28M	$-45.80M	$-46.32M	$-16.16M	$-45.43M	$-16.92M	$-14.19M	$-13.86M	$-15.97M	$-21.48M	$-101.13M
Low Forecast	$-60.92M	$-61.01M	$-61.09M	$-60.95M	$-84.16M	$-84.96M	$-86.15M	$-56.23M	$-58.08M	$-76.17M	$-45.43M	$-79.76M	$-66.89M	$-65.35M	$-23.96M	$-21.48M	$-151.69M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.78%	0.81%	0.75%	1.21%	0.56%	0.09%

Keros Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KROS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Keros Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Dec 22	Mar 22	Sep 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	7	3	3	6	3	2	4	3	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	$8.80M	$7.78M	$7.09M	$6.05M	$3.55M	$1.98M
Avg Forecast	$3.82M	$4.54M	$5.40M	$6.42M	$780.24K	$668.78K	$668.78K	$668.78K	$2.16M	$18.16M	$1.73M	$10.14M	$15.21M	$56.18M	$4.99M	$2.93M	$3.90M
High Forecast	$5.73M	$6.81M	$8.10M	$9.63M	$1.17M	$1.00M	$1.00M	$1.00M	$3.60M	$27.25M	$1.73M	$15.21M	$22.82M	$84.26M	$5.99M	$2.93M	$3.90M
Low Forecast	$1.91M	$2.27M	$2.70M	$3.21M	$390.10K	$334.39K	$334.39K	$334.39K	$720.18K	$9.08M	$1.73M	$5.07M	$7.61M	$28.09M	$3.99M	$2.93M	$3.90M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.87%	0.51%	0.13%	1.21%	1.21%	0.51%

Keros Therapeutics's average Quarter SG&A projection for Jun 24 is $1.73M, based on 3 Wall Street analysts, with a range of $1.73M to $1.73M. The forecast indicates a -80.32% fall compared to KROS last annual SG&A of $8.80M (Jun 23).

Keros Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Dec 22	Mar 22	Sep 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	7	3	3	6	3	2	4	3	3
EPS	-	-	-	-	-	-	-	-	-	-	-	$-1.27	$-1.15	$-1.09	$-1.01	$-0.60	$-0.70
Avg Forecast	$-1.02	$-1.02	$-1.03	$-1.02	$-1.41	$-1.43	$-1.45	$-1.43	$-1.41	$-1.28	$-1.26	$-1.34	$-1.12	$-1.10	$-0.86	$-0.59	$-0.37
High Forecast	$-0.36	$-0.36	$-0.36	$-0.36	$-0.49	$-0.50	$-0.51	$-1.27	$-1.28	$-0.45	$-1.26	$-0.47	$-0.39	$-0.38	$-0.86	$-0.59	$-0.37
Low Forecast	$-1.69	$-1.69	$-1.69	$-1.69	$-2.33	$-2.35	$-2.39	$-1.56	$-1.61	$-2.11	$-1.26	$-2.21	$-1.85	$-1.81	$-0.86	$-0.59	$-0.37
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.95%	1.02%	0.99%	1.17%	1.01%	1.89%

According to undefined Wall Street analysts, Keros Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KROS previous annual EPS of $NaN (undefined).

Keros Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IPSC	Century Therapeutics	$1.26	$15.00	1090.48%	Buy
NGM	NGM Biopharmaceuticals	$1.54	$16.50	971.43%	Buy
AVTE	Aerovate Therapeutics	$2.66	$13.00	388.72%	Hold
FENC	Fennec Pharmaceuticals	$4.64	$15.75	239.44%	Buy
LRMR	Larimar Therapeutics	$6.08	$20.33	234.38%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
ANAB	AnaptysBio	$20.31	$52.00	156.03%	Buy
ERAS	Erasca	$2.64	$6.50	146.21%	Buy
MLYS	Mineralys Therapeutics	$12.60	$30.00	138.10%	Buy
KZR	Kezar Life Sciences	$7.49	$17.50	133.64%	Buy
REPL	Replimune Group	$11.23	$24.20	115.49%	Buy
SNDX	Syndax Pharmaceuticals	$15.95	$34.30	115.05%	Buy
KROS	Keros Therapeutics	$54.14	$102.60	89.51%	Buy
IDYA	IDEAYA Biosciences	$25.54	$46.58	82.38%	Buy
BOLT	Bolt Biotherapeutics	$0.57	$1.00	75.44%	Hold
MGTX	MeiraGTx	$5.82	$9.00	54.64%	Buy
HRMY	Harmony Biosciences	$32.79	$48.86	49.01%	Buy
EWTX	Edgewise Therapeutics	$31.95	$45.00	40.85%	Buy
JANX	Janux Therapeutics	$48.96	$61.20	25.00%	Buy

KROS Forecast FAQ

Is Keros Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Keros Therapeutics (KROS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of KROS's total ratings.

What is KROS's price target?

Keros Therapeutics (KROS) average price target is $102.6 with a range of $96 to $107, implying a 89.51% from its last price of $54.14. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Keros Therapeutics stock go up soon?

According to Wall Street analysts' prediction for KROS stock, the company can go up by 89.51% (from the last price of $54.14 to the average price target of $102.6), up by 97.64% based on the highest stock price target, and up by 77.32% based on the lowest stock price target.

Can Keros Therapeutics stock reach $80?

KROS's average twelve months analyst stock price target of $102.6 supports the claim that Keros Therapeutics can reach $80 in the near future.

What is Keros Therapeutics's current price target trend?

2 Wall Street analysts forecast a $103.5 price target for Keros Therapeutics (KROS) this month, up 91.17% from its last price of $54.14. Compared to the last 3 and 12 months, the average price target increased by 86.55% and increased by 88.40%, respectively.

What are Keros Therapeutics's analysts' financial forecasts?

Keros Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $59.52K (high $89.29K, low $29.76K), average EBITDA is $-11.904K (high $-5.95K, low $-17.854K), average net income is $-206M (high $-99.955M, low $-312M), average SG&A $2.79M (high $4.18M, low $1.39M), and average EPS is $-5.719 (high $-2.769, low $-8.628). KROS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $431.1K (high $646.64K, low $215.55K), average EBITDA is $-86.217K (high $-43.107K, low $-129K), average net income is $-148M (high $-51.749M, low $-244M), average SG&A $20.18M (high $30.27M, low $10.09M), and average EPS is $-4.095 (high $-1.433, low $-6.757).